BMND01

BMND01 is an investigational, fast-acting liquid formulation of N,N-Dimethyltryptamine (DMT) developed by Biomind Labs. It is primarily targeted for the treatment of treatment-resistant depression (TRD). The drug functions as a potent agonist of the serotonin 5-HT2A receptor, a mechanism common to classic psychedelics that is believed to facilitate rapid neural plasticity and therapeutic psychological breakthroughs. BMND01 is designed for sublingual administration, aiming to provide a more predictable and shorter-duration psychedelic experience (approximately 10-30 minutes) compared to other psychedelics like psilocybin or LSD. This shorter duration is intended to make the treatment more scalable and easier to integrate into standard clinical psychiatric settings.

Other names

N,N-DimethyltryptamineDMT